Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 45Breast Neoplasms 20Myelodysplastic Syndromes 19Prostatic Neoplasms 12Neoplasms 12Leukemia, Myelomonocytic, Chronic 12Carcinoma, Hepatocellular 10Stomach Neoplasms 9Recurrence 9Carcinoma, Non-Small-Cell Lung 8Neoplasm Metastasis 7Esophageal Neoplasms 7Uterine Cervical Neoplasms 6Sarcoma 6Ovarian Neoplasms 6Multiple Myeloma 6Lung Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Melanoma 5Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Biphenotypic, Acute 4Cholangiocarcinoma 4Thrombocythemia, Essential 3

Interventions

PM 01183 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastrointestinal Malignancies × Injections × Clear all
NCT05229588 2025-08-15

Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations

HonorHealth Research Institute

Phase 2 Completed
8 enrolled
Gastrointestinal

Gastrointestinal Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡